Inovio Pharmaceuticals says its DNA cervical cancer vaccine produced promising results in an early-stage study, with one dose group registering "unprecedented T-cell responses" for five out of six patients. The vaccine company says that VGX-3100, its vaccine to treat precancerous cervical dysplasias and cervical cancers caused by human papillomavirus types 16 and 18, will be ready to go into Phase II in the first quarter of next year. Inovio release